Amgen - Medical Professionals

Patient Assistance Programs

Support Programs - Overview

Information for Patients

Neulasta®, NEUPOGEN® and You

Eligibility for Benefits

Filing Insurance Claims

SAFETY NET® Foundation

Claims Appeals

Glossary

Eligibility Screener

Claims Appeals

In the event of a denied claim for Neulasta® (pegfilgrastim) or NEUPOGEN® (Filgrastim), your insurance plan will send you a copy of your claim with an explanation of benefits (EOB) indicating why your claim was denied. Although your insurer should be familiar with NEUPOGEN® therapy, you should follow up on all denials. It is very important that you follow up on denials for Neulasta®, because your insurer may be unfamiliar with it since it is a newer therapy. If, after follow-up, there is still a dispute, you may request a special review.

Consider working with your provider and the Reimbursement Connection® to pursue your claim appeal—it may ultimately be resolved in your favor. Your physician can help explain the medical rationale for the use of the product.

If you have any questions not answered by this guide, please feel free to call the Reimbursement Connection® at 1-800-272-9376, Monday through Friday, from 9 a.m. to 8 p.m. (ET).

Continue to SAFETY NET®.

Return to Information for Patients main page.

Neulasta® Indication and Important Product Safety Information

Neulasta® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Important Product Safety Information

Splenic rupture (including fatal cases), acute respiratory distress syndrome, and sickle cell crises have been reported. Allergic reactions, including anaphylaxis, have also been reported. The majority of these reactions occurred upon initial exposure. However, in rare cases, allergic reactions, including anaphylaxis, recurred within days after discontinuing anti-allergic treatment.
In a placebo-controlled trial, bone pain occurred at a higher incidence in Neulasta®-treated patients as compared to placebo-treated patients (31% vs 26%). The most common adverse events reported in either placebo- or active-controlled trials were consistent with the underlying cancer diagnosis and its treatment with chemotherapy, with the exception of bone pain.

footer